Scholarlink

Objective <p>To evaluate changes in hospital outcomes for infants with neonatal opioid withdrawal syndrome (NOWS) assessed by the Finnegan Tool before (10/1/2019 to 12/31/2019;pre-epoch) and after (7/1/2021 to 3/31/2022;post-epoch) publication of the 2020 AAP NOWS clinical report.</p> Study design <p>This subgroup analysis included infants with NOWS assessed with the Finnegan Tool and enrolled in the INFORM NOW study (pre- and post-epoch 183 and 267 infants respectively).</p> Results <p>No differences were found between epochs in initiation or length of pharmacologic treatment(LOT), or length of stay(LOS). Outcomes were modified by opioid type: LOT was 20% shorter (aMR=0.80; 95%CI:[0.69,0.93]) and LOS was 16% shorter (aMR=0.84; 95%CI:[0.73,0.96]) for buprenorphine treated infants post- compared to pre-epoch, while LOT and LOS were longer in the post-epoch for those treated with methadone.</p> Conclusion <p>There was no difference in outcomes before and after publication of the AAP report. However, the type of postnatal opioid did modify study results.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Temporal trends in outcomes for infants with neonatal opioid withdrawal managed with the Finnegan scoring tool: Insights from the INFORM NOW Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月16日

查看全文
  • Lori A. Devlin,
  • Walter K. Kraft,
  • Denise C. Babineau,
  • Evan Rhodes,
  • Abhik Das,
  • Margaret Crawford,
  • Stephanie Merhar,
  • Sucheta Telang,
  • Lawrence Leeman,
  • Gregory M. Sokol,
  • Namasivayam Ambalavanan,
  • Sara B. DeMauro,
  • Richard W. Hall,
  • Scott A. Lorch,
  • Augusto Santos Schmidt,
  • Abhik Das,
  • Namasivayam Ambalavanan,
  • Richard W. Hall,
  • Walter K. Kraft,
  • Lawrence Leeman,
  • Scott A. Lorch,
  • Stephanie L. Merhar,
  • Lori A. Devlin,
  • Gregory M. Sokol,
  • Brenda Poindexter,
  • Jonathan M. Davis

摘要

Objective

To evaluate changes in hospital outcomes for infants with neonatal opioid withdrawal syndrome (NOWS) assessed by the Finnegan Tool before (10/1/2019 to 12/31/2019;pre-epoch) and after (7/1/2021 to 3/31/2022;post-epoch) publication of the 2020 AAP NOWS clinical report.

Study design

This subgroup analysis included infants with NOWS assessed with the Finnegan Tool and enrolled in the INFORM NOW study (pre- and post-epoch 183 and 267 infants respectively).

Results

No differences were found between epochs in initiation or length of pharmacologic treatment(LOT), or length of stay(LOS). Outcomes were modified by opioid type: LOT was 20% shorter (aMR=0.80; 95%CI:[0.69,0.93]) and LOS was 16% shorter (aMR=0.84; 95%CI:[0.73,0.96]) for buprenorphine treated infants post- compared to pre-epoch, while LOT and LOS were longer in the post-epoch for those treated with methadone.

Conclusion

There was no difference in outcomes before and after publication of the AAP report. However, the type of postnatal opioid did modify study results.